肿瘤基因组：肿瘤疾病中的性别差异图谱

IF 16.6 2区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nucleic Acids Research Pub Date : 2024-11-13 DOI:10.1093/nar/gkae1003

Xinyi Shen, Yintao Zhang, Jiamin Li, Ying Zhou, Samuel D Butensky, Yechi Zhang, Zongwei Cai, Andrew T DeWan, Sajid A Khan, Hong Yan, Caroline H Johnson, Feng Zhu

{"title":"肿瘤基因组：肿瘤疾病中的性别差异图谱","authors":"Xinyi Shen, Yintao Zhang, Jiamin Li, Ying Zhou, Samuel D Butensky, Yechi Zhang, Zongwei Cai, Andrew T DeWan, Sajid A Khan, Hong Yan, Caroline H Johnson, Feng Zhu","doi":"10.1093/nar/gkae1003","DOIUrl":null,"url":null,"abstract":"The NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% of clinically actionable oncology genes are sex-biased, indicating differences in drug efficacy. Research has identified sex differences in non-reproductive cancers, highlighting the need for comprehensive sex-based cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing sex-based differences in cancer (https://idrblab.org/OncoSexome/) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) and microbial landscape (SML). SDR covers sex-based differences in 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent risk factors; SML demonstrates 1386 microbes with sex-differential abundances associated with cancer development. OncoSexome is unique in illuminating multifaceted influences of biological sex on cancer, providing both external and endogenous contributors to cancer development and describing sex-based differences for the broadest oncological classes. Given the increasing global research interest in sex-based differences, OncoSexome is expected to impact future precision oncology practices significantly.","PeriodicalId":19471,"journal":{"name":"Nucleic Acids Research","volume":"163 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"OncoSexome: the landscape of sex-based differences in oncologic diseases\",\"authors\":\"Xinyi Shen, Yintao Zhang, Jiamin Li, Ying Zhou, Samuel D Butensky, Yechi Zhang, Zongwei Cai, Andrew T DeWan, Sajid A Khan, Hong Yan, Caroline H Johnson, Feng Zhu\",\"doi\":\"10.1093/nar/gkae1003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% of clinically actionable oncology genes are sex-biased, indicating differences in drug efficacy. Research has identified sex differences in non-reproductive cancers, highlighting the need for comprehensive sex-based cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing sex-based differences in cancer (https://idrblab.org/OncoSexome/) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) and microbial landscape (SML). SDR covers sex-based differences in 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent risk factors; SML demonstrates 1386 microbes with sex-differential abundances associated with cancer development. OncoSexome is unique in illuminating multifaceted influences of biological sex on cancer, providing both external and endogenous contributors to cancer development and describing sex-based differences for the broadest oncological classes. Given the increasing global research interest in sex-based differences, OncoSexome is expected to impact future precision oncology practices significantly.\",\"PeriodicalId\":19471,\"journal\":{\"name\":\"Nucleic Acids Research\",\"volume\":\"163 1\",\"pages\":\"\"},\"PeriodicalIF\":16.6000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nucleic Acids Research\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1093/nar/gkae1003\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nucleic Acids Research","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1093/nar/gkae1003","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

美国国立卫生研究院的性别生物变量（SABV）政策强调了基于性别的差异在精准肿瘤学中的重要性。超过 50% 的临床可操作肿瘤基因具有性别差异，这表明药物疗效存在差异。研究发现了非生殖性癌症中的性别差异，这凸显了对基于性别的综合癌症数据的需求。因此，我们开发了 OncoSexome，这是一个描述癌症性别差异的多维知识库 (https://idrblab.org/OncoSexome/)，涵盖四个关键主题：抗肿瘤药物和反应 (SDR)、肿瘤相关生物标记物 (SBM)、风险因素 (SRF) 和微生物景观 (SML)。SDR 涵盖了 2051 种抗癌药物的性别差异；SBM 描述了 12 551 种性别差异生物标记物；SRF 说明了 350 种性别依赖性风险因素；SML 展示了 1386 种与癌症发展相关的微生物丰度性别差异。OncoSexome 在阐明生物性别对癌症的多方面影响方面是独一无二的，它提供了癌症发展的外部和内部因素，并描述了最广泛的肿瘤类别中基于性别的差异。鉴于全球对性别差异的研究兴趣与日俱增，OncoSexome 预计将对未来的精准肿瘤学实践产生重大影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

OncoSexome: the landscape of sex-based differences in oncologic diseases

The NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% of clinically actionable oncology genes are sex-biased, indicating differences in drug efficacy. Research has identified sex differences in non-reproductive cancers, highlighting the need for comprehensive sex-based cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing sex-based differences in cancer (https://idrblab.org/OncoSexome/) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) and microbial landscape (SML). SDR covers sex-based differences in 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent risk factors; SML demonstrates 1386 microbes with sex-differential abundances associated with cancer development. OncoSexome is unique in illuminating multifaceted influences of biological sex on cancer, providing both external and endogenous contributors to cancer development and describing sex-based differences for the broadest oncological classes. Given the increasing global research interest in sex-based differences, OncoSexome is expected to impact future precision oncology practices significantly.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nucleic Acids Research 生物-生化与分子生物学

CiteScore

27.10

自引率

4.70%

发文量

1057

审稿时长

2 months

期刊介绍： Nucleic Acids Research (NAR) is a scientific journal that publishes research on various aspects of nucleic acids and proteins involved in nucleic acid metabolism and interactions. It covers areas such as chemistry and synthetic biology, computational biology, gene regulation, chromatin and epigenetics, genome integrity, repair and replication, genomics, molecular biology, nucleic acid enzymes, RNA, and structural biology. The journal also includes a Survey and Summary section for brief reviews. Additionally, each year, the first issue is dedicated to biological databases, and an issue in July focuses on web-based software resources for the biological community. Nucleic Acids Research is indexed by several services including Abstracts on Hygiene and Communicable Diseases, Animal Breeding Abstracts, Agricultural Engineering Abstracts, Agbiotech News and Information, BIOSIS Previews, CAB Abstracts, and EMBASE.